Tibet Duo Rui Pharmaceutical Co

Tibet Duo Rui Pharmaceutical Co Book Value per Share

The Book Value per Share of Tibet Duo Rui Pharmaceutical Co (301075.SZ) as of Nov 3, 2026 is 7.18 CNY. In the previous year, Book Value per Share was 8.46 CNY — a change of -15.10% (lower).

Book Value per Share

7.18CNY

YoY

-15.10%

Last updated:

Book Value per Share of Tibet Duo Rui Pharmaceutical Co is 2025 7.18 CNY. Book Value per Share of Tibet Duo Rui Pharmaceutical Co was 2024 8.46 CNY. It decreases by -15.10% lower compared to the previous year.

The Tibet Duo Rui Pharmaceutical Co Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
0.93 CNY
Jan 1, 2019
1.88 CNY
Jan 1, 2020
3.03 CNY
Jan 1, 2021
9.91 CNY
Jan 1, 2022
9.39 CNY
Jan 1, 2023
9.65 CNY
Jan 1, 2024
8.46 CNY
Jan 1, 2025
7.18 CNY
The Tibet Duo Rui Pharmaceutical Co Book Value per Share history
YEARBook Value per ShareYoY
7.18CNY-15.10%
8.46CNY-12.35%
9.65CNY+2.73%
9.39CNY-5.22%
9.91CNY+227.16%
3.03CNY+61.17%
1.88CNY+102.61%
0.93CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Duo Rui Pharmaceutical Co Stock analysis

What does Tibet Duo Rui Pharmaceutical Co do? Tibet Duo Rui Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical preparations and their raw materials. The company's core product, sodium acetate ringer injection, is used for supplementing body fluids, regulating electrolyte balance, and correcting acidosis. Additional products include compound electrolyte injection, compound mannitol injection, and cefotaxime sodium for injection, which are sold to healthcare providers and hospitals. The firm targets the pharmaceutical market segment focused on fluid and electrolyte management and antibiotic treatments. The company's revenue streams are derived from the sale of its proprietary chemical preparations, with sodium acetate ringer injection representing a key product line. Compound electrolyte injection and compound mannitol injection cater to specific medical needs, while cefotaxime sodium for injection serves as an antibiotic solution. These products are distributed to hospitals and healthcare facilities within China's pharmaceutical distribution network. Tibet Duo Rui Pharmaceutical's business model centers on developing and commercializing specialized injectable solutions for clinical use. The firm's product portfolio addresses critical healthcare requirements, including fluid replacement, electrolyte regulation, and infection treatment. Sales are directed toward medical institutions that require these specialized pharmaceutical products for patient care. Tibet Duo Rui Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Duo Rui Pharmaceutical Co stock

Book Value per Share of Tibet Duo Rui Pharmaceutical Co is 7.18 CNY in 2025.

Book Value per Share of Tibet Duo Rui Pharmaceutical Co changed from 8.46 CNY to 7.18 CNY, representing a -15.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Tibet Duo Rui Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Tibet Duo Rui Pharmaceutical Co

All Key Metrics — Tibet Duo Rui Pharmaceutical Co